Dorothy Carvalho, APRN
Primary Care · Farmington, CTNPI 1649813429
Payments from drug & device makers
What this record shows
It is spread thinly across 8 manufacturers, the largest accounting for just 23.2%. Reporting peaked in 2022 at $266 and has fallen 62.8% since, to $99 in 2025.
Across 10 payments — averaging $43.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$100
- Incyte Corporation$99
- C. R. Bard, Inc. & Subsidiaries$66
- Rochester Medical Corporation$51
- Urovant Sciences Inc$40
- Olympus America Inc.$28
- plus $48 from 2 others
What the payments were for
- Food & beverage$23254%
- Education$19946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 1 | $100 |
| Incyte Corporation | 1 | $99 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $66 |
| Rochester Medical Corporation | 1 | $51 |
| Urovant Sciences Inc | 2 | $40 |
| Olympus America Inc. | 1 | $28 |
| Palette Life Sciences, Inc. | 1 | $27 |
| Antares Pharma, Inc. | 1 | $20 |
How this compares
$431 in reported general payments places this provider in the 55th percentile of 111 primary care providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 16 | $11,374 |
| Estradiol | 32 | $2,263 |
| Methenamine Hippurate | 24 | $1,653 |
| Tamsulosin Hcl | 124 | $1,315 |
| Finasteride | 46 | $589 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 28 | $397 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $394 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $271 |
Paid to pharmacies, not to this prescriber.
Other primary care in Farmington
- Zachary HillFarmington$716
- Tara MahonFarmington$706
- Christina OsadchyFarmington$434
- Kelly NolinEnfield$16K
- Deanna BallardDanbury$7K
- Jacqueline VelezBridgeport$7K
- Joyce WallHamden$5K
- Catherine KrenickyPawcatuck$5K
- Christopher AndersonGroton$5K
- Carolyn BrownMiddlebury$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.